PODD
HealthcareInsulet Corp. · Medical - Devices · $11B
What is Insulet Corp.?
Insulet Corporation makes insulin delivery systems designed to simplify life for people with insulin-dependent diabetes. Its flagship Omnipod platform has built a loyal global user base across North America, Europe, and beyond.
Insulet generates revenue by selling its tubeless Omnipod insulin delivery devices and related consumables through pharmacy channels, independent distributors, and direct sales. The disposable pod design creates a recurring purchase cycle, supporting predictable demand. Products reach customers across the United States, Canada, Europe, the Middle East, and Australia.
Incorporated in 2000 and headquartered in Acton, Massachusetts.
- Omnipod tubeless insulin delivery system
- Disposable self-adhesive pod worn up to three days
- Wireless handheld personal diabetes manager
- Pharmacy and direct distribution channels
Is PODD a Good Stock to Buy?
UQS Score rates PODD as Good overall.
Growth stands out as the strongest pillar, reflecting Insulet's expanding global footprint in diabetes care. The Risk pillar also rates Good, suggesting the business carries a manageable risk profile relative to sector peers.
Moat and Valuation both rate Neutral, indicating the competitive advantage is not yet considered wide, and the current price does not offer an obvious discount.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PODD pay dividends?
No — Insulet Corp. does not currently pay a dividend.
Insulet does not currently pay a dividend. As a growth-oriented medical device company, it reinvests available capital into product development, geographic expansion, and manufacturing scale rather than returning cash to shareholders through distributions.
When does PODD report earnings?
Insulet Corporation reports earnings on a quarterly cadence, typical for US-listed equities.
Quarterly results have generally reflected continued expansion in international markets and growing adoption of the Omnipod platform. Revenue trends have been supported by the recurring consumable nature of the pod business.
For the most recent quarter's results, visit Insulet Corporation's investor relations page directly.
PODD Price History
-47.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Insulet Corp.?
Based on Insulet Corp.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Insulet Corporation do?
Insulet develops and sells the Omnipod insulin delivery system, a tubeless, self-adhesive pod worn on the body for up to three days. It serves people with insulin-dependent diabetes through pharmacy and distributor channels in the US, Canada, Europe, the Middle East, and Australia.
Does PODD pay dividends?
No, PODD does not pay a dividend. Insulet reinvests its capital into growth initiatives, including international expansion and product innovation, rather than distributing cash to shareholders.
When does PODD report earnings?
Insulet reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of Insulet's official website.
Is PODD a good stock to buy?
UQS Score rates PODD as Good, with a particularly Strong Growth pillar. Moat and Valuation are both Neutral, meaning competitive positioning and pricing merit attention. The full pillar breakdown is available to Pro members on UQS Score.
Is PODD overvalued?
PODD's Valuation pillar rates Neutral under the UQS framework, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Pro members can view the detailed valuation metrics behind this assessment.
What is PODD's market cap bracket?
Insulet Corporation is classified as a large-cap company, placing it among the more established players in the medical device space.
Who founded Insulet Corporation?
Insulet was founded by John Brooks, who developed the concept for a tubeless insulin delivery device. The company was incorporated in 2000 and is now headquartered in Acton, Massachusetts.
Is PODD a long-term quality indicator?
The UQS framework rates PODD Good overall, with a Strong Growth pillar and Good Risk profile — both relevant to long-term quality assessment. Moat rates Neutral, which is a factor worth monitoring for investors focused on durable competitive advantage.
Unlock Full PODD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access detailed financial metrics behind each pillar
- ✓Compare PODD against sector peers side by side
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
PODD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | 31.7 | 13.8 | 55.0 | 0.0 | 36.9 | 59.7 | -33.4 |
| Aug 1, 2026 | 65.1 | 67.8 | 55.0 | 82.1 | 64.9 | 54.9 | 0.0 |
| Jul 25, 2026 | 65.1 | 67.9 | 55.0 | 82.1 | 64.9 | 55.1 | -0.3 |
| Jul 23, 2026 | 65.4 | 68.0 | 55.0 | 82.1 | 64.9 | 56.6 | +0.3 |
| Jul 22, 2026 | 65.1 | 67.8 | 55.0 | 82.1 | 64.9 | 55.1 | +0.2 |
| Jul 21, 2026 | 64.9 | 67.7 | 55.0 | 82.1 | 64.9 | 54.2 | -0.2 |
| Jul 17, 2026 | 65.1 | 67.8 | 55.0 | 82.1 | 64.9 | 54.7 | -0.2 |
| Jul 15, 2026 | 65.3 | 68.0 | 55.0 | 82.1 | 64.9 | 55.7 | +0.1 |
| Jul 11, 2026 | 65.2 | 67.9 | 55.0 | 82.1 | 64.9 | 55.3 | — |
PODD — Pillar Breakdown
Quality
— 13.8/100 (25%)Insulet Corp. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Insulet Corp. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Insulet Corp. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 59.7/100 (15%)Insulet Corp. trades at a reasonable valuation with decent earnings yield and FCF multiples.
How many years of FCF the market cap represents.
Moat
— 55/100 (25%)Insulet Corp. has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PODD.
Score Composition
Financial Data
More Stock Analysis
How is the PODD UQS Score Calculated?
The UQS (Unified Quality Score) for Insulet Corp. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Insulet Corp.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Insulet Corp. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.